Some of the dual inhibitors targeting pBRD4 and PLK1, PI3K, ALK, HDAC, p38α, and CDK9, were reported to have a strong downregulation effect on c-Myc or N-Myc in acute myeloid leukaemia, neuroblastoma, castration-resistant prostate cancer, pancreatic cancer, hepatocellular, and colorectal carcinoma (reviewed by [262]). The gene discussed is MYCN; the disease is neuroblastoma.